Regeneron to buy genetic testing firm 23andMe for $256 million
May 19 (Reuters) - Drugmaker Regeneron Pharmaceuticals REGN.O has agreed to buy genetic testing firm 23andMe Holding MEHCQ.PK for $256 million, the companies said on Monday. (Reporting by Mariam Sunny in Bengaluru; Editing by Leroy Leo) ((Mariam.ESunny@thomsonreuters.com))
Recent news on Chrome Holding Co
See all newsBrief: Chrome Holding Co Enters Into Stock Purchase Agreement With Bambu Ventures
23andMe seeks approval of larger, $50 million data breach settlement
Brief: 23andMe Holding Co Changes Name to Chrome Holding Co
Brief: 23andMe Holding Says Debtors Repay All Outstanding Indebtedness, Terminate Loan Agreement
founder